Telomir Pharmaceuticals, Inc., recently disclosed preclinical results indicating the effectiveness of its licensed molecule Telomir-1 in addressing Type 2 diabetes mellitus. The results of the study showcased significant reductions in fasting plasma glucose levels, improvements in oral glucose homeostasis, and a reversal of insulin resistance to levels near pre-diabetic states. These positive findings were further reinforced by notable enhancements in Homeostatic Model Assessment of Insulin Resistance values, a conventional measure used to evaluate insulin sensitivity and resistance in individuals.
Additionally, the study revealed that the effects observed with Telomir-1 also included increased survival rates among the treated subjects. Telomir Pharmaceuticals emphasized that Telomir-1 serves to target oxidative stress and beta-cell damage by normalizing iron metabolism. Partnering with the India-based research organization Pentagrit, Telomir conducted assessments on two variations of Telomir-1, administered orally at varying doses, using zebrafish models. The collaboration led to promising results, indicating the molecule's potential in addressing age-related issues and demonstrating age-reversal effects, such as extending healthy lifespan, enhancing mobility, and reversing age-related decline.
Telomir Pharmaceuticals is currently expanding its focus to investigate Telomir-1's impact on several other areas apart from Type 2 diabetes mellitus. The company is exploring its effects on conditions like progeria, diabetic mouse models, Alzheimer's disease, osteoarthritis, and other inflammatory diseases. These initiatives aim to evaluate the molecule's potential in mitigating accelerated aging, cognitive decline, neurodegeneration, and managing joint health and inflammatory conditions in aging individuals. The positive preclinical results presented by Telomir Pharmaceuticals have also reflected in the market, with TELO stock experiencing a 15.4% increase to $4.905.